Leerink Swann reaffirmed their market perform rating on shares of Myriad Genetics, Inc. (NASDAQ:MYGN) in a report released on Monday, Marketbeat.com reports. The firm currently has a $31.00 target price on the stock. Leerink Swann also issued estimates for Myriad Genetics’ Q1 2018 earnings at $0.20 EPS, Q2 2018 earnings at $0.26 EPS, Q3 2018 earnings at $0.26 EPS, Q4 2018 earnings at $0.31 EPS, FY2018 earnings at $1.03 EPS, Q1 2019 earnings at $0.26 EPS, Q2 2019 earnings at $0.28 EPS, Q3 2019 earnings at $0.29 EPS, Q4 2019 earnings at $0.30 EPS and FY2019 earnings at $1.13 EPS.

A number of other equities research analysts have also issued reports on the company. Zacks Investment Research raised Myriad Genetics from a hold rating to a buy rating and set a $28.00 target price on the stock in a research report on Monday, July 17th. J P Morgan Chase & Co reissued an underweight rating and issued a $16.00 target price on shares of Myriad Genetics in a research report on Friday, June 30th. BidaskClub raised Myriad Genetics from a hold rating to a buy rating in a research report on Saturday, June 17th. Cowen and Company reissued a hold rating and issued a $25.00 target price on shares of Myriad Genetics in a research report on Friday, July 14th. Finally, Piper Jaffray Companies reissued a hold rating and issued a $22.00 target price on shares of Myriad Genetics in a research report on Friday, July 14th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have assigned a buy rating to the stock. The company has a consensus rating of Hold and a consensus target price of $24.20.

Myriad Genetics (NASDAQ MYGN) opened at 36.51 on Monday. Myriad Genetics has a 12-month low of $15.15 and a 12-month high of $37.14. The company has a 50-day moving average price of $32.41 and a 200-day moving average price of $24.80. The firm has a market cap of $2.50 billion, a P/E ratio of 114.45 and a beta of 0.28.

Myriad Genetics (NASDAQ:MYGN) last announced its earnings results on Tuesday, August 8th. The company reported $0.30 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.26 by $0.04. Myriad Genetics had a return on equity of 9.67% and a net margin of 2.83%. The business had revenue of $200.50 million for the quarter, compared to analyst estimates of $193.71 million. During the same quarter last year, the firm earned $0.36 EPS. Myriad Genetics’s revenue for the quarter was up 7.5% compared to the same quarter last year. On average, analysts predict that Myriad Genetics will post $1.02 earnings per share for the current year.

WARNING: “Myriad Genetics, Inc. (MYGN) Rating Reiterated by Leerink Swann” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.watchlistnews.com/myriad-genetics-inc-mygn-rating-reiterated-by-leerink-swann/1612492.html.

In other Myriad Genetics news, Director John T. Henderson sold 30,000 shares of the business’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $30.30, for a total transaction of $909,000.00. Following the transaction, the director now owns 52,524 shares of the company’s stock, valued at approximately $1,591,477.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.20% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently modified their holdings of the company. SG Americas Securities LLC bought a new position in shares of Myriad Genetics during the 2nd quarter worth approximately $101,000. Riverhead Capital Management LLC boosted its stake in shares of Myriad Genetics by 80.9% during the 2nd quarter. Riverhead Capital Management LLC now owns 4,161 shares of the company’s stock worth $107,000 after acquiring an additional 1,861 shares during the period. Ameritas Investment Partners Inc. bought a new position in shares of Myriad Genetics during the 1st quarter worth approximately $112,000. Fiduciary Trust Co. bought a new position in shares of Myriad Genetics during the 2nd quarter worth approximately $113,000. Finally, Ronald Blue & Co. LLC bought a new position in shares of Myriad Genetics during the 2nd quarter worth approximately $208,000.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.